 |
 Video: What is a Stock Split?
|
|
|
| Kezar Life Sciences is a clinical-stage biotechnology company, discovering and developing small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer. Co.'s primary product candidate, KZR-616, is a selective immunoproteasome inhibitor. KZR-261 is the main clinical candidate from Co.'s research platform targeting the Sec61 translocon and the protein secretion pathway for the discovery and development of small molecule therapeutics for oncology and autoimmune indications. KZR-261 has demonstrated anti-tumor activity in preclinical models of both solid and hematologic malignancies by targeting multiple pathways driving tumor growth and survival. According to our Kezar Life Sciences stock split history records, Kezar Life Sciences has had 0 splits. | |
|
Kezar Life Sciences (KZR) has 0 splits in our Kezar Life Sciences stock split history database.
Looking at the Kezar Life Sciences stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Kezar Life Sciences shares, starting with a $10,000 purchase of KZR, presented on a split-history-adjusted basis factoring in the complete Kezar Life Sciences stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
06/22/2018 |
|
| End date: |
04/15/2024 |
|
| Start price/share: |
$17.79 |
|
| End price/share: |
$0.81 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
-95.45% |
|
| Average Annual Total Return: |
-41.19% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$455.40 |
|
| Years: |
5.82 |
|
|
|
|
|
